In Brief: VHA/Abbott
Executive Summary
VHA/Abbott: Sign 10-year agreement for VHA to purchase Abbott's injectable and inhalation anesthetics. Abbott estimates the agreement will generate sales of $1 bil. The agreement includes proprietary and generic drugs, plus generic drugs planned for introduction after patent expiration. Abbott and VHA will work together on a procedure-based model for anesthesia drug utilization that will enable VHA organizations to predict and manage costs associated with anesthetic use. Sanofi Winthrop also signs long-term agreement with VHA that involves volume purchases of the Carpuject syringe delivery system line of products...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth